Companies › BioNTech SE
23 active drug programs in 49 registered trials: 27 Phase 1, 11 Phase 2, 9 Phase 3, 2 Phase 4; Oncology, Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tozinameran Spike glycoprotein vaccine antigen | SARS-COV-2 | Phase 4 | COVID-19 Vaccines; COVID-19; Diabetes Mellitus, Type 1 | Apr 2027 |
| Pumitamig (BNT327, BMS-986545, PM8002) | – | Phase 3 | Extensive-stage Small-cell Lung Cancer; Breast Neoplasms; Pancreatic Ductal Adenocarcinoma (PDAC); Recurrent Glioblastoma … | Jun 2027 |
| BNT323/DB-1303 anti-HER2 antibody-drug conjugate with topoisomerase I inhibitor payload | ERBB2 | Phase 3 | Endometrial Cancer | Mar 2028 |
| BNT324 B7-H3 antibody-drug conjugate | B7H3 | Phase 3 | Metastatic Castration-resistant Prostate Cancer; Advanced Lung Cancer | Sep 2028 |
| RO7198457 | – | Phase 2 | Colorectal Cancer Stage II; Pancreatic Cancer | Nov 2026 |
| BNT166a mRNA-based Mpox vaccine | – | Phase 2 | Mpox (Monkeypox) | Jun 2027 |
| BNT113 HPV16-targeting immunotherapy | – | Phase 2 | Unresectable Head and Neck Squamous Cell Carcinoma | Apr 2029 |
| BNT314 | – | Phase 1 | Advanced Malignant Solid Tumor; Metastatic Colorectal Cancer | Nov 2026 |
| BNT351 HIV-neutralizing antibody | – | Phase 1 | HIV -1 Infection | Nov 2026 |
| BNT164a1 Multi-antigen RNA vaccine for active immunization against tuberculosis | – | Phase 1 | Tuberculosis | Jan 2027 |
| BNT164b1 Multi-antigen RNA vaccine for active immunization against tuberculosis | – | Phase 1 | Tuberculosis | Jan 2027 |
| BNT3212 Unclear - not specified in registry text | – | Phase 1 | Advanced Solid Tumor | Nov 2027 |
| BNT168 RNA-based vaccine | – | Phase 1 | HIV -1 Infection | Feb 2028 |
| BNT326 | – | Phase 1 | Advanced Solid Tumor; Non-small Cell Lung Cancer | Mar 2028 |
| BNT323 HER2-targeted antibody-drug conjugate (trastuzumab conjugated with panmitrimer) | ERBB2 | Phase 1 | Locally Advanced Breast Cancer | Aug 2029 |
| BNT116 mRNA vaccine encoding tumor-associated antigens | – | Phase 1 | Non-Small Cell Lung Cancer | Feb 2030 |
| BNT316 anti-CTLA-4 antibody | CTLA4 | Phase 1 | Non-Small Cell Lung Cancer | Feb 2030 |
| anti-B7-H3 antibody conjugated to topoisomerase I inhibitor anti-B7-H3 antibody-drug conjugate with topoisomerase I inhibitor | B7H3 | Phase 1 | Non-Small Cell Lung Cancer | Feb 2030 |
| anti-HER3 antibody conjugated to topoisomerase I inhibitor anti-HER3 antibody-drug conjugate with topoisomerase I inhibitor | HER3 | Phase 1 | Non-Small Cell Lung Cancer | Feb 2030 |
| BNT329 CA19-9-targeting monoclonal antibody | – | Phase 1 | Advanced Solid Cancers | May 2030 |
| BNT3214 Unclear - early phase exploratory drug | – | Phase 1 | Advanced Solid Tumor Cancer | Oct 2030 |
| BNT317 Unclear - code-named investigational therapy | – | Phase 1 | Advanced Solid Tumor | Apr 2031 |
| BNT163 Anti-viral RNA vaccine for active immunization against HSV-2 | HSV2 | Phase 1 | Genital Herpes Simplex Type 2 | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04894435 | Tozinameran | Phase 2 | COVID-19 | Infectious disease | Nov 2024 |
| NCT04894435 | Tozinameran | Phase 2 | COVID-19 | Infectious disease | Nov 2024 |
| NCT07300839 | Tozinameran | Phase 3 | COVID-19 | Infectious disease | Sep 2026 |
| NCT05432583 | BNT163 | Phase 1 | Genital Herpes Simplex Type 2 | Infectious disease | Oct 2026 |
| NCT04161755 | RO7198457 | Phase 1 | Pancreatic Cancer | Oncology | Nov 2026 |
| NCT04486378 | RO7198457 | Phase 2 | Colorectal Cancer Stage II | Oncology | Nov 2026 |
| NCT06150183 | BNT314 | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Nov 2026 |
| NCT07392372 | BNT351 | Phase 1 | HIV -1 Infection | Infectious disease | Nov 2026 |
| NCT05415267 | Tozinameran | Phase 3 | COVID-19 | Infectious disease | Dec 2026 |
| NCT05547464 | BNT164a1 | Phase 1 | Tuberculosis | Infectious disease | Jan 2027 |
| NCT05547464 | BNT164b1 | Phase 1 | Tuberculosis | Infectious disease | Jan 2027 |
| NCT07798648 | Tozinameran | Phase 3 | COVID-19 Vaccines | Infectious disease | Apr 2027 |
| NCT07798648 | Tozinameran | Phase 3 | COVID-19 Vaccines | Infectious disease | Apr 2027 |
| NCT07798648 | Tozinameran | Phase 3 | COVID-19 Vaccines | Infectious disease | Apr 2027 |
| NCT06449209 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 2 | Extensive-stage Small-cell Lung Cancer | Oncology | Jun 2027 |
| NCT07379580 | BNT166a | Phase 2 | Mpox (Monkeypox) | Infectious disease | Jun 2027 |
| NCT07730450 | Tozinameran | Phase 4 | COVID-19 Vaccines | Infectious disease | Aug 2027 |
| NCT06452654 | Tozinameran | Phase 4 | Diabetes Mellitus, Type 1 | Infectious disease | Oct 2027 |
| NCT07147348 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2027 |
| NCT07147348 | BNT3212 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2027 |
| NCT07255404 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Dec 2027 |
| NCT07297212 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 2 | Recurrent Glioblastoma | Oncology | Jan 2028 |
| NCT07698600 | BNT168 | Phase 1 | HIV -1 Infection | Infectious disease | Feb 2028 |
| NCT07070232 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2028 |
| NCT06340568 | BNT323/DB-1303 | Phase 3 | Endometrial Cancer | Oncology | Mar 2028 |
| NCT07070232 | BNT326 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2028 |
| NCT06449222 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 2 | Locally Advanced Breast Cancer | Oncology | Aug 2028 |
| NCT06892548 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 1 | Advanced Lung Cancer | Oncology | Sep 2028 |
| NCT06892548 | BNT324 | Phase 1 | Advanced Lung Cancer | Oncology | Sep 2028 |
| NCT06841055 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Oct 2028 |
| NCT07111520 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 1 | Non-small Cell Lung Cancer | Oncology | Nov 2028 |
| NCT07111520 | BNT326 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Nov 2028 |
| NCT06712316 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Jan 2029 |
| NCT06712355 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 3 | Extensive-stage Small-cell Lung Cancer | Oncology | Apr 2029 |
| NCT04534205 | BNT113 | Phase 2 | Unresectable Head and Neck Squamous Cell Carcinoma | Oncology | Apr 2029 |
| NCT07579221 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Aug 2029 |
| NCT06827236 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 1 | Locally Advanced Breast Cancer | Oncology | Aug 2029 |
| NCT06827236 | BNT323 | Phase 1 | Locally Advanced Breast Cancer | Oncology | Aug 2029 |
| NCT07173751 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 3 | Breast Neoplasms | Oncology | Dec 2029 |
| NCT05142189 | BNT116 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Feb 2030 |
| NCT05142189 | BNT316 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Feb 2030 |
| NCT05142189 | anti-B7-H3 antibody conjugated to topoisomerase I inhibitor | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Feb 2030 |
| NCT05142189 | anti-HER3 antibody conjugated to topoisomerase I inhibitor | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Feb 2030 |
| NCT07186842 | BNT329 | Phase 1 | Advanced Solid Cancers | Oncology | May 2030 |
| NCT07455734 | BNT3214 | Phase 1 | Advanced Solid Tumor Cancer | Oncology | Oct 2030 |
| NCT07079631 | Pumitamig (BNT327, BMS-986545, PM8002) | Phase 1 | Metastatic Colorectal Cancer | Oncology | Dec 2030 |
| NCT07079631 | BNT314 | Phase 1 | Metastatic Colorectal Cancer | Oncology | Dec 2030 |
| NCT07365995 | BNT324 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Oncology | Feb 2031 |
| NCT06750185 | BNT317 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2031 |
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Sichuan Baili Pharmaceutical MediLink Therapeutics (Suzhou) Shanghai JMT-Bio ImmunityBio Shanghai Institute Of Biological Products
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.